Howell A, DeFriend D, Robertson J, Blamey R, Walton P
CRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.
Lancet. 1995 Jan 7;345(8941):29-30. doi: 10.1016/s0140-6736(95)91156-1.
We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.
我们用一种新的特异性抗雌激素药物（ICI 182780）治疗了19例对他莫昔芬耐药的晚期乳腺癌患者，该药物在动物研究中无激动剂活性。13例（69%）患者在他莫昔芬治疗进展后，对每月一次的ICI 182780肌肉注射有反应（7例部分缓解，6例病情无变化），中位缓解持续时间为18个月，副作用最小。初步证据表明该药物对肝脏或下丘脑-垂体轴无影响。ICI 182780似乎是一种治疗晚期和早期乳腺癌的有前景的新药。
